Prestige Consumer (PBH) Q2 2025 Earnings Report

Prestige Consumer Healthcare Inc reported Q2 2025 results showcasing resilience amid supply chain constraints and inflationary pressures, with revenues of $284 million reflecting a 0.97% decline YoY, largely attributed to Clear Eyes supply chain issues. Despite the minor decline in sales, the company's diversified portfolio enabled offsetting growth in the International segment, particularly through Hydralyte. Key financial metrics demonstrate stable earnings, with earnings per share (EPS) slightly increasing to $1.09, a 1.85% growth from the previous year. The company continues to progress debt reduction strategies, reducing total debt by $40 million this quarter, resulting in a leverage decline to 2.7x. Management remains optimistic about future performance supported by strategic brand initiatives and capital allocation.